Genetron Holdings Limited logo
Genetron Holdings Limited GTH
report update icon

Quarterly report 2022-Q4
added 06-06-2026

Genetron Holdings Limited Income Statement 2022-2011 | GTH

Brief overview of financial results at Genetron Holdings Limited

This overview is based on financial performance over the past five years. According to figures from Genetron Holdings Limited, revenue changed from 101 million yuan to 651 million yuan over five years. The cumulative result was +544.1%, corresponding to roughly 45.1% per year. The company expanded its revenue base at a high speed.

The gross result shifted from 26.8 million yuan to 281 million yuan, or +949.2%. The gross margin was 26.5% at the start and 43.2% at the end. The expansion indicates stronger pricing power or better control of direct costs.

EBITDA was −134 million yuan at the beginning and −702 million yuan at the end of the period (−425.6%). EBITDA lagged revenue, showing weaker operating momentum. The EBITDA share of revenue changed from −132.2% to −107.9%. A wider margin confirms stronger operating efficiency.

Comparing the endpoints shows a move from −421 million yuan to −811 million yuan. Larger losses indicate rising pressure on the business.

What the figures show

The financial profile remains mixed, with strengths and risks moving in different directions. The financial profile benefits from positive operating leverage, a larger revenue base and better sales economics. The main areas of concern are a weaker final result and a low EBITDA margin. Further direction will depend on top-line growth, operating profitability, and net income.

Annual Income Statement Genetron Holdings Limited

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

404 M 1.54 B 7.41 B - - 116 M - - - - - -

Shares

464 M 461 M 301 M 125 M 114 M 67.7 M - - - - - -

Historical Prices

0.87 3.35 24.6 - - - - - - - - -

Net Income

-811 M -503 M -3.07 B -676 M -465 M -421 M - - - - - -

Revenue

651 M 532 M 424 M 323 M 225 M 101 M - - - - - -

Cost of Revenue

369 M 194 M 164 M 178 M 132 M - - - - - - -

Gross Profit

281 M 338 M 260 M 145 M 92.7 M 26.8 M - - - - - -

Operating Income

-702 M -518 M -268 M -307 M -233 M - - - - - - -

EBITDA

-702 M -518 M -268 M -307 M -233 M -134 M - - - - - -

Operating Expenses

983 M 856 M 529 M 452 M 326 M 181 M - - - - - -

General and Administrative Expenses

- - 126 M 117 M 88.2 M 45.5 M - - - - - -

All numbers in CNY currency

Quarterly Income Statement Genetron Holdings Limited

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

464 M - - - 461 M - - - 301 M - - - 125 M - - - 114 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-811 M - - - -503 M - - - -3.07 B - - - -676 M - - - -465 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

651 M - - - 532 M - - - 424 M - - - 323 M - - - 225 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

369 M - - - 194 M - - - 164 M - - - 178 M - - - 132 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

281 M - - - 338 M - - - 260 M - - - 145 M - - - 92.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-702 M - - - -518 M - - - -268 M - - - -307 M - - - -233 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-702 M - - - -518 M - - - -268 M - - - -307 M - - - -233 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

983 M - - - 856 M - - - 529 M - - - 452 M - - - 326 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in CNY currency

The income statement is one of the three key financial reports of a company Genetron Holdings Limited (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Celcuity Celcuity
CELC
$ 88.34 -2.0 % $ 4.13 B usaUSA
Myriad Genetics Myriad Genetics
MYGN
$ 5.7 0.71 % $ 528 M usaUSA
NeoGenomics NeoGenomics
NEO
$ 14.24 1.64 % $ 1.82 B usaUSA
Neogen Corporation Neogen Corporation
NEOG
$ 9.61 -2.24 % $ 2.08 B usaUSA
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Natera Natera
NTRA
$ 264.69 0.18 % $ 36.2 B usaUSA
OPKO Health OPKO Health
OPK
$ 1.17 -0.85 % $ 812 M usaUSA
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
Pacific Biosciences of California Pacific Biosciences of California
PACB
$ 1.4 1.45 % $ 420 M usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
Co-Diagnostics Co-Diagnostics
CODX
$ 2.21 -3.07 % $ 2.94 M usaUSA
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Neuronetics Neuronetics
STIM
$ 1.88 -2.59 % $ 124 M usaUSA
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
Twist Bioscience Corporation Twist Bioscience Corporation
TWST
$ 92.44 -1.88 % $ 5.53 B usaUSA
Exact Sciences Corporation Exact Sciences Corporation
EXAS
- - $ 19.8 B usaUSA
CareDx, Inc CareDx, Inc
CDNA
$ 37.61 -0.45 % $ 2 B usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
- - $ 10.6 B niderlandNiderland
Soleno Therapeutics Soleno Therapeutics
SLNO
- - $ 2.69 B usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
$ 7.47 -5.44 % $ 29.8 M israelIsrael
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 227.9 8.61 % $ 25.3 B usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
- -34.28 % $ 263 K israelIsrael
Biomerica Biomerica
BMRA
$ 1.6 0.34 % $ 3.68 M usaUSA
Invitae Corporation Invitae Corporation
NVTA
- - $ 21.2 M usaUSA
Organovo Holdings Organovo Holdings
ONVO
- -2.3 % $ 19.4 M usaUSA
OpGen OpGen
OPGN
- -16.95 % $ 1.54 M usaUSA
Anixa Biosciences Anixa Biosciences
ANIX
$ 3.75 6.53 % $ 122 K usaUSA
PerkinElmer PerkinElmer
PKI
- -0.91 % $ 14.7 B usaUSA
Mettler-Toledo International Mettler-Toledo International
MTD
$ 1 331.87 3.57 % $ 27.5 B schweizSchweiz
DexCom DexCom
DXCM
$ 70.48 -1.33 % $ 27.5 B usaUSA
Psychemedics Corporation Psychemedics Corporation
PMD
- -1.84 % $ 15.3 M usaUSA
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 170.32 1.82 % $ 13.4 B irlandaIrlanda
Quotient Limited Quotient Limited
QTNT
- -11.32 % $ 1.1 M schweizSchweiz
T2 Biosystems T2 Biosystems
TTOO
- -39.35 % $ 313 K usaUSA
Renalytix AI plc Renalytix AI plc
RNLX
- 5.66 % $ 22.7 M britainBritain
Syneos Health Syneos Health
SYNH
- - $ 4.46 B usaUSA
Meridian Bioscience Meridian Bioscience
VIVO
- - $ 1.49 B usaUSA
Surmodics Surmodics
SRDX
- - $ 608 M usaUSA